News
We send the latest information from SMC Laboratories.
The comparison of NASH-HCC and other HCC models
Liver cancer is the sixth most common cancer in the world and the third most common cause of cancer-related de…
Drug efficacy study in NASH mouse model
We would like to introduce a paper published by our client using our non-alcoholic steatohepatitis (NASH) mode…
Published papers with IPF model
We would like to share with you some examples of studies that our clients have often asked us about using the …
Why is Chronic Kidney Disease so hard to research?
Between 9 – 12% of the worlds population suffers from Chronic Kidney Disease (CKD), but with no cure, ho…
What is proteinuria’s role in evaluating the progression of CKD?
When discussing our mouse models for chronic kidney disease (CKD), we are often asked about proteinuria as a u…
What is the relationship between NASH and Liver Cancer?
You may know that liver cancer is one of the most prevalent cancers, but do you know about its relationship wi…
SMC attend BIO Partnering at JPM Week!
We are pleased to announce that SMC Laboratories will be virtually attending the BIO One-on-One Partnering eve…
Long-COVID, COVID-19 variants, and the emergence of pulmonary fibrosis in recovered COVID-19 patients
COVID-19 is a virus belonging to the beta-coronavirus class, similar to the virus that causes severe acute res…
Marvel Biosciences has published a press release regarding the MB-207 efficacy evaluation study for liver fibrosis provided by SMC
Marvel Biosciences, which is our client, has announced the results of pharmacology study using a STAM™ m…
SMC announces Presentation of New Data at the KDDW 2021
We are pleased to announce the acceptance of our abstracts, “Molecular Pathogenesis of Non-Alcoholi…